Amazon's Stake in Anthropic Could Be Worth Over $400 Billion If the AI Start-Up's Reported IPO Valuation Holds. Should Jeff Bezos' Amazon Investors Care?

Amazon’s stake in Anthropic has surged to $190.4B as of June 30 (from $74.2B at March 31), following Amazon’s $8B investment in 2024 and $5B in 2025, giving it a 21% reported stake. Secondary markets are now valuing Anthropic at ~$2T (vs ~$1.2T earlier), and Amazon’s stake could be worth about $420B if the IPO targets that valuation. The filing of the confidential S-1 and the steep mark-to-market uplift are strongly positive for investors, though a valuation “crater” risk remains if the IPO disappoints.

Analysis

AMZN is increasingly being valued less like a pure operating company and more like a platform with a sizable, monetizable venture book. That matters because it creates a hidden source of funding optionality for AI capex and buybacks without tapping the balance sheet, which can support sentiment even if core margins are only gradually improving. The catch is liquidity: until there is an actual IPO, lockup, and some selling, the value is only a paper mark and should not be capitalized at 1:1.

The first-order read-through for NVDA is narrower than the headlines suggest. A richly priced IPO can encourage frontier-model spending and keep training/inference demand elevated, but a very high valuation also invites scrutiny of unit economics, which could force discipline on model vendors and reduce the pace of compute burn. The more durable second-order effect is on sector optics: if AMZN can surface value from a startup stake, investors will start asking which other megacaps are underappreciating embedded assets, but that is a rerating argument, not a near-term EPS driver.

The contrarian risk is that the market has already partially discounted this as a sum-of-the-parts story, so any delay, weak book, or IPO discount to secondary marks could trigger a sharp give-back in sentiment. Falsifiers are straightforward: a pricing range materially below recent secondary levels, a post-listing slump, or no evidence that proceeds are being recycled into AWS/AI spend or repurchases within 1-3 quarters. Over 6-18 months, the real variable is whether AMZN converts paper gains into capital returns or strategic reinvestment; if not, the premium may fade.

Key Decisions for Investors

• Accumulate AMZN on weakness over the next 1-3 months; use a staged entry and treat this as a rerating trade rather than an earnings trade. Upside is a modest multiple lift from embedded-asset recognition; downside is limited unless the IPO is priced below recent secondary marks or delayed.
• Buy AMZN Jan-2027 call spreads only if the filing confirms a large IPO range and the lockup structure does not create an immediate supply overhang. This is the cleanest way to express upside from a public mark while capping premium at risk.
• No direct NFLX expression; this is not a streaming read-through. If forced to hedge portfolio beta, use QQQ or XLY rather than a stock-specific short, since the signal is valuation rerating rather than sector rotation.
• Watch NVDA only as a secondary beneficiary: add on dips if the IPO roadshow signals aggressive compute expansion plans. If the company emphasizes efficiency and moderation in capex, that would argue against adding exposure.
• Set a falsification alert: if Anthropic prices 20%+ below the latest meaningful secondary valuation, trim any AMZN add and fade the SOTP narrative until the lockup window clears.